M. Sharma

发表

A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart® Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies

M. Maris, E. Winer, P. Kaminker, 2022, Blood.

Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors

C. Horak, M. Sznol, A. El-Khoueiry, 2023, Cancer Research.

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Ashutosh Kumar Singh, A. Drilon, K. Ching, 2023, Cancer Discovery.

Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.

K. Papadopoulos, D. Rasco, G. Fleming, 2023, Journal of Clinical Oncology.